A UK SaaS B2B health tech delivering fast, customized, targeted, regulatory clinical & scientific medicines information to pharmaceuticals & biotechs in our Webby Award-Winning app Medsii.
Current Status
We recently Q4 2022 pivoted to a pure B2B model and have just signed the following as paying customers: Viatris (owns Viagra, Xanax, Lipitor and more), UCB and Almirall. We now also have dozens of pharma companies in our pipeline.
Problem or Opportunity
Pharmaceuticals, biotechs, researchers, & hospitals/clinics do not receive trusted, regulatory-grade approved intelligence on medicines as soon as regulators publish it. But speed is now critically important as the pandemic’s rapid acceleration of vaccines’ design, clinical trials, regulatory approvals & rollouts have changed the game
Competitors, however, have legacy technology & processes, often using weekly or monthly emails.
Solution (product or service)
Medsii PRO provides pharmaceuticals, biotechs & healthcare professionals rapid, customized regulatory medicines intelligence alerts. Our award-winning UK categorizes by topic (clinical trial alert, safety update, scientific discovery, regulatory approval), class ( cardiovascular, gynaecology, cancer etc.), condition (breast cancer, diabetes, dementia, stroke etc.), & medicine(s) and also gives our users the ability to easily customize and combine these on our front end. Subscribers also get notifications on peer-trending alerts of interest using our AI.
Business model
B2B data as a service license model to stakeholders in pharmaceuticals and biotechs: Regulatory Affairs, Medical Affairs, Pharmacovigilance, Pharmacoepidemiology, Clinical Operations (Site operations, Clinical trial supplies, Trial monitoring), Clinical Research, Competitive Intelligence, Commercial Brand Teams, Market Access & Reimbursement, Legal & Compliance, Translational R&D, Public Affairs, Government Affairs, Pharmaceutical Development.
B2B White Label service to retail pharmacies, health insurers & more to provide health information, cross-sell and up-sell products.
